|
|
| | Glutaminase-IN-1 Basic information |
| Product Name: | Glutaminase-IN-1 | | Synonyms: | Glutaminase-IN-1;CB839 derivative;Glutamise-IN-1;Glutaminase inhibitor 1;2-Pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]-1,3,4-selenadiazol-2-yl]-;GlutaminaseIN1,Glutaminase IN 1;Glutaminase-IN-1, 10 mM in DMSO | | CAS: | 2247127-79-1 | | MF: | C26H24F3N7O3Se | | MW: | 618.47 | | EINECS: | | | Product Categories: | | | Mol File: | 2247127-79-1.mol |  |
| | Glutaminase-IN-1 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 125 mg/mL (202.11 mM) | | pka | 11.56±0.70(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | Glutaminase-IN-1 Usage And Synthesis |
| Uses | Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC50 of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity. | | in vivo | Glutaminase-IN-1(10 mg/kg, s.c.) reduced the size and weight of the HCT116 tumor, and statistical analysis showed that the 40% reduction in tumor weight by CPD20 is statistically significant. Glutaminase-IN-1 could statistically significantly prolong the survival of H22-bearing mice[1]. | | References | [1] Chen Z, et al. Novel 1,3,4-Selenadiazole Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity. J Med Chem. 2018 Dec 13. DOI:10.1021/acs.jmedchem.8b01198 |
| | Glutaminase-IN-1 Preparation Products And Raw materials |
|